Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Gross Margin (2016 - 2018)

Historic Gross Margin for Theravance Biopharma (TBPH) over the last 6 years, with Q1 2018 value amounting to 90.07%.

  • Theravance Biopharma's Gross Margin rose 83700.0% to 90.07% in Q1 2018 from the same period last year, while for Mar 2018 it was 69.49%, marking a year-over-year decrease of 224700.0%. This contributed to the annual value of 60.81% for FY2017, which is 199000.0% down from last year.
  • As of Q1 2018, Theravance Biopharma's Gross Margin stood at 90.07%, which was up 83700.0% from 30.99% recorded in Q4 2017.
  • Theravance Biopharma's 5-year Gross Margin high stood at 98.26% for Q3 2016, and its period low was 124.84% during Q4 2014.
  • Over the past 5 years, Theravance Biopharma's median Gross Margin value was 88.34% (recorded in 2016), while the average stood at 67.45%.
  • In the last 5 years, Theravance Biopharma's Gross Margin crashed by -2248400bps in 2014 and then skyrocketed by 1426200bps in 2015.
  • Over the past 5 years, Theravance Biopharma's Gross Margin (Quarter) stood at 124.84% in 2014, then skyrocketed by 114bps to 17.78% in 2015, then soared by 349bps to 79.87% in 2016, then tumbled by -61bps to 30.99% in 2017, then soared by 191bps to 90.07% in 2018.
  • Its Gross Margin was 90.07% in Q1 2018, compared to 30.99% in Q4 2017 and 76.96% in Q3 2017.